UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 10, 2007 (August 9, 2007)
PAR PHARMACEUTICAL COMPANIES, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
Delaware
(State or other jurisdiction of
incorporation or organization) | | File Number 1-10827
(Commission File Number) | | 22-3122182
(I.R.S. Employer
Identification No.) |
| | | | | |
300 Tice Boulevard, Woodcliff Lake, New Jersey
(Address of principal executive offices) | | | | 07677
(Zip Code) |
Registrant’s telephone number, including area code: (201) 802-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01 Other Events.
Mr. LePore who has been serving as President and Chief Executive Officer of the Company since September 2006, has agreed to continue serving in these positions for the next three years. Additionally, Mr. LePore will take on the role of Chairman of the Board of Directors of the Company (the “Board”) and Mr. Joe Smith, a current director, was designated as lead director of the Board.
Certain statements in this Current Report onForm 8-K constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent that any statements made in this Current Report onForm 8-K contain information that is not historical, such statements are essentially forward-looking and are subject to certain risks and uncertainties, including the risks and uncertainties discussed from time to time in the Company’s filings with the SEC, including its Annual Reports onForm 10-K, Quarterly Reports on Form 10-Q and Current Reports onForm 8-K. Any forward-looking statements included in this Current Report onForm 8-K are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated as of: August 10, 2007
| | | | | |
| | PAR PHARMACEUTICAL COMPANIES, INC.
(Registrant)
| |
| | /s/ Thomas Haughey | |
| | Name: | Thomas Haughey | |
| | Title: | Executive Vice President
and General Counsel | |
| |
